Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Support for innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD. Drug targets in the areas of inflammation and proteostasis will be considered high priority.
Característiques principals
The RFP supports:
  • Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.
  • n vivo testing of novel lead compounds, biologics, vaccines, or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.
    This RFP does NOT support target identification, target validation, assay development, high-throughput and high-content screening. IND-enabling work is supported through ADDF’s PACT RFP.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    https://www.alzdiscovery.org/research-and-grants/funding-opportunities/accelerating-drug-discovery-for-ftd
    Applications:
    https://addf.fluxx.io/
    Dotació
    $100,000-$150,000 based on stage and scope of research.
    Durada
    One year with potential for follow-on funding.
    AVÍS IMPORTANT
    Letter of Intent: May 20th, 2022
    Invited Full Proposal: July 30th, 2022

    Arxius

    Arxiu
    Request for Proposals_ Accelerating Drug Discovery for Frontotemporal Degeneration _ Alzheimer's Drug Discovery Foundation.pdf